Alexion to acquire genetic medicine company LogicBio Therapeutics
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a deal worth $68 million. As per the terms of the deal, shareholders of the NASDAQ-listed LogicBio Therapeutics will be paid $2.07 per share by Alexion, AstraZeneca Rare Disease. The latter was formed following last year’s $39 billion […]